The study focuses on a rare skin cancer called Cutaneous T-cell lymphoma, which often appears as a form known as Mycosis fungoides. Participants will use a cream that contains the active ingredient delgocitinib, a type of JAK inhibitor that works by blocking signals that can cause inflammation and abnormal cell growth. The purpose of the study is to evaluate the safety and tolerability of this topical treatment.
People who join the study will apply the cream to affected skin areas twice each day for about four months. During this time they will attend regular clinic visits where doctors will look at the skin and record changes using a scoring system called mSWAT, which rates how much of the skin is involved and how severe the patches are. Participants will also answer simple questionnaires about itching (called pruritus) and how the skin condition affects daily life. Small skin samples may be taken to explore how the medicine works, and a gentle test may be performed to see if the skin barrier improves. The study ends after the treatment period, and the collected information helps researchers understand whether the cream is safe and how well it works for this condition.
Denmark 
